Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

Mazzaferro, Vincenzo; Romito, Raffaele; Schiavo, Marcello; Mariani, Luigi; Camerini, Tiziana; Bhoori, Sherrie; Capussotti, Lorenzo; Calise, Fulvio; Pellicci, R; Belli, Giulio; Tagger, A.; Colombo, Massimo; Bonino, Ferruccio; Majno, Pietro; Llovet, Josep M.

doi:10.1002/hep.21415

Cited by 351 publications

(336 citation statements)

References 44 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…Another RCT in Italy did not detect effects of IFN therapy on early recurrence but late recurrence, with more than 2 years of interval, seemed to be reduced among IFN responders [403]. These data are compatible with the hypothesis that de novo carcinogenesis was prevented by successful antiviral therapy.…”

Section: Tertiary Prevention Of Hcv-related Hccsupporting

confidence: 61%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Introduction The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. 123Hepatol Int (2010) 4: 439-474 DOI 10.1007/s12072-010-9165-7 Results Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

show abstract

Section: Tertiary Prevention Of Hcv-related Hccsupporting

confidence: 61%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[18][19][20] In light of the effects of adjuvant IFN therapy on HCC recurrence after surgical resection, it has been suggested that adjuvant IFN therapy may reduce late recurrences after surgery or prolong the disease-free survival, although this has not been validated statistically in a general study population. 4,21 Taken together, we believe that these findings deserve a careful re-evaluation to determine whether adjuvant IFN therapy may prevent or retard HCC recurrence in a particular subgroup that has a very high risk of recurrence. Thus, the objective of the current study was to investigate whether postoperative, adjuvant pegylated-IFN (Peg-IFN) therapy can reduce the rate of recurrence after curative surgical resection in patients with MTA1-positive HCC who are at high risk of recurrence.…”

Section: Introductionmentioning

confidence: 83%

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Lee

Chung

Kim

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND: Metastatic tumor antigen 1 (MTA1) overexpression is closely associated with postoperative recurrence of hepatocellular carcinoma (HCC). It has been suggested that pegylated interferon (Peg-IFN) can prevent the occurrence of HCC in patients who have chronic viral hepatitis. In this study, the authors examined whether postoperative adjuvant Peg-IFN therapy can reduce the recurrence of MTA1-positive HCC after curative surgical resection. METHODS: In this case-control study, 93 patients with MTA1-positive HCC who underwent curative surgical resection were prospectively enrolled. The median patient age was 53 years (range, 27-78); there were 65 men and 28 women; the etiology was hepatitis B virus (HBV) in 77 patients, hepatitis C virus (HCV) in 6 patients, and non-HBV/non-HCV in 10 patients; 31 patients received Peg-IFN (Peg-INTRON V R ) subcutaneously at a dose of 50 lg per week for 12 months (the Peg-IFN group); and the remaining 62 patients were followed only and did not receive any adjuvant therapies (control group). Patients were followed every 1 to 3 months for a median of 24 months. RESULTS: HCC recurred postoperatively in 26 of 93 patients (28%), and 9 patients (10%) died during follow-up. The overall cumulative recurrence rates were significantly lower in the Peg-IFN group than in the control group (7% and 14% vs 24% and 34% at 1 year and 2 years, respectively; P <.05). In addition, the 1-year and 2-year cumulative survival rates were higher in the Peg-IFN group compared with the control group (100% vs 93% and 100% vs 87%, respectively; P <.05). In multivariate analysis, the receipt of adjuvant Peg-IFN therapy, in addition to having a lower Cancer of the Liver Italian Program score and being a woman, was an independent, favorable factor for a lower risk of postoperative recurrence. INTRODUCTIONHepatocellular carcinoma (HCC) is characterized by its high prevalence and aggressiveness, which accounts for a major cause of death in the Far East and in sub-Saharan Africa. 1,2 Clinically, only less than 10% to 20% of patients with HCC have previously been considered candidates for surgical resection. 3-5 Furthermore, frequent marginal or remote recurrence of HCC in the remnant liver is another insurmountable problem in light of long-term prognosis. 6,7 According to previous studies, postoperative recurrence rates after surgical resection reached approximately 50% to 80%, whereas our recent studies reported relatively lower recurrence rates. [8][9][10][11][12] Metastatic tumor antigen 1 (MTA1) plays an important role in the tumorigenesis and metastasis of various human malignancies, such as liver, breast, prostate, lung, colorectal, and gastric cancers. 13,14 Our recent study demonstrated that MTA1 overexpression is associated with frequent postoperative recurrence as well as microvascular invasion compared with negative MTA1 status and, consequently, can be used a valuable predictor of worse postoperative outcomes for patients who have HCC with respect to recurrence and survival. 15 Such findings are i...

show abstract

“…IFN has been studied as adjuvant therapy after liver resection or ablation of HCC in HCV infected cirrhotics because of its anti-carcinogenic properties (89)(90)(91)(92)(93)(94)(95). Among 209 patients with HCV who underwent curative resection for HCC, 70 patients underwent IFN therapy (89).…”

Section: Ifn After Liver Resection or Ablation To Prevent Or Treat Rementioning

confidence: 99%

Viral hepatitis and hepatocellular carcinoma: etiology and management

Zamor

deLemos

Russo

2017

J. Gastrointest. Oncol.

123

102

View full text Add to dashboard Cite

Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) EpidemiologyIt is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2). Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths (3). The annual incidence of HCC is estimated to be <1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. Because of worldwide and geographic variations in HBV incidence, the burden of HBV related HCC also varies. Asian-Pacific and sub-Saharan Africa represent the highest incidence of HCC worldwide. Much lower risk of HBV associated HCC is seen in the United States with less than 20% incidence. Due to its diversity, Europe has different areas: low risk (18%) in West and North and high risk (51%) East and South (4). Occult HBV or subclinical infection as defined by detectable HBV DNA in the liver but hepatitis B surface antigen (HBsAg) seronegativity is now recognized as increased risk for HCC. The risk is most notable in those over the age of 50 (5,6). Recently published data reveal that in China, the age-standardized death due to HBV-related HCC and cirrhosis in 2013 was 10.95 and 4.91 per 100,000 people (7). Fifty-five percent of all HCC cases worldwide are reported from China (8).In 1991, the WHO recommended the integration of the HBV vaccine into national immunization programs in countries with an HBV carrier prevalence of 8% or higher by 1995 and in all other countries by 1997 (9). The universal infant vaccination rate in sub-Saharan Africa was initially quite low at 5% in 2000 but increased to 72% by 2012. Parts of the Pacific region had the lowest immunization rates, but by 2012 had increased to the highest rates at 91%. Taiwan has an exceptionally higher This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.

show abstract

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

Cited by 351 publications

References 44 publications

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Viral hepatitis and hepatocellular carcinoma: etiology and management

Contact Info

Product

Resources

About